1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Oral Medications 1.2.3 Temozolomide 1.2.4 Radiosensitizers 1.2.5 Nitrosoureas Drugs 1.2.6 Radiation Therapy 1.2.7 Chemotherapy 1.3 Market by Application 1.3.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Ambulatory Surgical Centers 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Perspective (2016-2027) 2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Growth Trends by Regions 2.2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Share by Regions (2016-2021) 2.2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2022-2027) 2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Industry Dynamic 2.3.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Trends 2.3.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers 2.3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Challenges 2.3.4 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue 3.1.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue (2016-2021) 3.1.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Players (2016-2021) 3.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue 3.4 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio 3.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2020 3.5 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players Head office and Area Served 3.6 Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service 3.7 Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Type 4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Type (2016-2021) 4.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2022-2027) 5 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Application 5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Application (2016-2021) 5.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027) 6.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type 6.2.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) 6.2.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) 6.2.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027) 6.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application 6.3.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) 6.3.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) 6.3.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027) 6.4 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country 6.4.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) 6.4.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) 6.4.3 United States 6.4.3 Canada 7 Europe 7.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027) 7.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type 7.2.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) 7.2.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) 7.2.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027) 7.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application 7.3.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) 7.3.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) 7.3.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027) 7.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country 7.4.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) 7.4.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027) 8.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type 8.2.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027) 8.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application 8.3.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027) 8.4 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region 8.4.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027) 9.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type 9.2.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) 9.2.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) 9.2.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027) 9.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application 9.3.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) 9.3.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) 9.3.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027) 9.4 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country 9.4.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) 9.4.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027) 10.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type 10.2.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027) 10.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application 10.3.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027) 10.4 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country 10.4.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Astrazeneca 11.1.1 Astrazeneca Company Details 11.1.2 Astrazeneca Business Overview 11.1.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 11.1.4 Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) 11.1.5 Astrazeneca Recent Development 11.2 Roche 11.2.1 Roche Company Details 11.2.2 Roche Business Overview 11.2.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 11.2.4 Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) 11.2.5 Roche Recent Development 11.3 GlaxoSmithKline 11.3.1 GlaxoSmithKline Company Details 11.3.2 GlaxoSmithKline Business Overview 11.3.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 11.3.4 GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) 11.3.5 GlaxoSmithKline Recent Development 11.4 Merck 11.4.1 Merck Company Details 11.4.2 Merck Business Overview 11.4.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 11.4.4 Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) 11.4.5 Merck Recent Development 11.5 Pfizer 11.5.1 Pfizer Company Details 11.5.2 Pfizer Business Overview 11.5.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 11.5.4 Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) 11.5.5 Pfizer Recent Development 11.6 AngioChem 11.6.1 AngioChem Company Details 11.6.2 AngioChem Business Overview 11.6.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 11.6.4 AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) 11.6.5 AngioChem Recent Development 11.7 Vascular Biogeneics 11.7.1 Vascular Biogeneics Company Details 11.7.2 Vascular Biogeneics Business Overview 11.7.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction 11.7.4 Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) 11.7.5 Vascular Biogeneics Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Oral Medications Table 3. Key Players of Temozolomide Table 4. Key Players of Radiosensitizers Table 5. Key Players of Nitrosoureas Drugs Table 6. Key Players of Radiation Therapy Table 7. Key Players of Chemotherapy Table 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 9. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 10. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (2016-2021) & (US$ Million) Table 11. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2016-2021) Table 12. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2022-2027) Table 14. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Trends Table 15. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers Table 16. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Challenges Table 17. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints Table 18. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Players (2016-2021) & (US$ Million) Table 19. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players (2016-2021) Table 20. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2020) Table 21. Ranking of Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Companies by Revenue (US$ Million) in 2020 Table 22. Global 5 Largest Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (CR5 and HHI) & (2016-2021) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service Table 25. Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million) Table 28. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2016-2021) Table 29. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million) Table 30. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million) Table 31. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Application (2016-2021) & (US$ Million) Table 32. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Application (2016-2021) Table 33. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million) Table 34. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million) Table 35. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million) Table 36. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million) Table 37. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million) Table 38. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million) Table 39. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million) Table 40. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million) Table 41. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million) Table 42. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million) Table 43. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million) Table 44. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million) Table 45. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million) Table 46. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million) Table 47. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million) Table 48. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million) Table 49. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million) Table 50. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million) Table 51. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2016-2021) & (US$ Million) Table 52. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2022-2027) & (US$ Million) Table 53. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million) Table 54. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million) Table 55. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million) Table 56. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million) Table 57. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million) Table 58. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million) Table 59. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million) Table 60. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million) Table 61. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million) Table 62. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million) Table 63. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million) Table 64. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million) Table 65. Astrazeneca Company Details Table 66. Astrazeneca Business Overview Table 67. Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product Table 68. Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million) Table 69. Astrazeneca Recent Development Table 70. Roche Company Details Table 71. Roche Business Overview Table 72. Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product Table 73. Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million) Table 74. Roche Recent Development Table 75. GlaxoSmithKline Company Details Table 76. GlaxoSmithKline Business Overview Table 77. GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product Table 78. GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million) Table 79. GlaxoSmithKline Recent Development Table 80. Merck Company Details Table 81. Merck Business Overview Table 82. Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product Table 83. Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million) Table 84. Merck Recent Development Table 85. Pfizer Company Details Table 86. Pfizer Business Overview Table 87. Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product Table 88. Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million) Table 89. Pfizer Recent Development Table 90. AngioChem Company Details Table 91. AngioChem Business Overview Table 92. AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product Table 93. AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million) Table 94. AngioChem Recent Development Table 95. Vascular Biogeneics Company Details Table 96. Vascular Biogeneics Business Overview Table 97. Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product Table 98. Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million) Table 99. Vascular Biogeneics Recent Development Table 100. Research Programs/Design for This Report Table 101. Key Data Information from Secondary Sources Table 102. Key Data Information from Primary Sources List of Figures Figure 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type: 2020 VS 2027 Figure 2. Oral Medications Features Figure 3. Temozolomide Features Figure 4. Radiosensitizers Features Figure 5. Nitrosoureas Drugs Features Figure 6. Radiation Therapy Features Figure 7. Chemotherapy Features Figure 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2020 VS 2027 Figure 9. Hospitals Case Studies Figure 10. Clinics Case Studies Figure 11. Ambulatory Surgical Centers Case Studies Figure 12. Recurrent Glioblastoma Multiforme (GBM) Treatment Report Years Considered Figure 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 14. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 15. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions: 2020 VS 2027 Figure 16. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2022-2027) Figure 17. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players in 2020 Figure 18. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2020 Figure 19. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2020 Figure 20. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2016-2021) Figure 21. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2022-2027) Figure 22. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 23. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027) Figure 24. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027) Figure 25. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027) Figure 26. United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 27. Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 28. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027) Figure 30. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027) Figure 31. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027) Figure 32. Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. France Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. U.K. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Nordic Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027) Figure 40. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027) Figure 41. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Region (2016-2027) Figure 42. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027) Figure 50. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027) Figure 51. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027) Figure 52. Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 53. Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 54. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027) Figure 56. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027) Figure 57. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027) Figure 58. Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 59. Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 60. UAE Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 61. Astrazeneca Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) Figure 62. Roche Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) Figure 63. GlaxoSmithKline Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) Figure 64. Merck Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) Figure 65. Pfizer Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) Figure 66. AngioChem Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) Figure 67. Vascular Biogeneics Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) Figure 68. Bottom-up and Top-down Approaches for This Report Figure 69. Data Triangulation Figure 70. Key Executives Interviewed

Astrazeneca Roche GlaxoSmithKline Merck Pfizer AngioChem Vascular Biogeneics